The effect of Telmisartan on lipid levels and proinflammatory cytokines in ESRD patients undergoing hemodialysis

Telmisartan acts as a partial selective agonist of PPARY, thus might alTect lipid and carbohydrate metabolisms. This study aimed to investigate the effect of Telmisartan on lipid profiles and Proinflammatory Cytokine (CRP) in ESRD patients. An observational study was conducted on ESRD patients with regular hemodialysis at least twice a week during the last three months, blood pressure predialytic >140/90 mmHg, and not using Telmisartan. Sixteen subjects were involved ( 12 male and four female). Pre-study levels of cholesterol. TG, HDL and LDL were normal. After three months of treatment with Telmisartan, the levels of cholesterol. TG. HDL and LDL were 127.31 mg/dl, 74 mg/dl, 50.06 mg/dl and 74.56 mg/dl, respectively, showing a decrease in lipid levels except for cholesterol. The level of CRP was slightly decreased after Telmisartan treatment from 0.47 ± 0.4^ mg/dl to 0.34 ± 0.33 mg/dl. Thus. Telmisartan has a promising effect on decreasing lipid and cytokine proinflammatory levels in ESRD patients with hemodialysis.